Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
A human RCT from Wuhan, China, showed that ALA therapy (1200 mg/d) for 7 days, could reduce a 30-day all-cause mortality rate (37.5%) in critical COVID-19 patients 535
-Boosts collagen production
10.1016/j.cbi.2020.109024 32 FengF
Ongoing & Emerging Research Heart Failure with Preserved Ejection Fraction Status: Phase 3 Ongoing Focus: HFpEF outcomes in obese patients Timeline: Results expected 2025-2026 NASH/MASH Status: Phase 3 Ongoing Focus: Hepatic steatosis and fibrosis improvement Timeline: Multiple trials in progress Obstructive Sleep Apnea Status: Phase 3 Ongoing (SURMOUNT-OSA) Focus: OSA severity reduction with weight loss Timeline: Results expected 2024 Pediatric Obesity Status: Phase 3 Ongoing Focus: Weight management in adolescents (12 years) Timeline: Early-phase research Research Resources How to Find More Trials 1
Researchers classify it as a "stable gastric pentadecapeptide" because of its unusual stability in the harsh acidic environment of the stomach
